In the Phase 3 trial, RHAPSODY, the IL-1α and IL-1β cytokine trap rilonacept effectively resolved active pericarditis recurrences and reduced the overall risk of recurrence during long-term treatment.12 Notably, patients who continued rilonacept treatment beyond 18 months experienced a 98% reduction in recurrence risk compared with those who discontinued rilonacept at that time (hazard ratio: 0.02; P < 0.0001).13 The gene discussed is IL1A; the disease is pericarditis.